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Background: Most commonly used mobilization methods for
ASCT include G-CSF, however no standard approach has been es-
tablished. Plerixafor (Mozobil), a competitive inhibitor of
CXCR4, when given with G-CSF mobilizes more CD34 cells/
apheresis resulting in a higher total CD34 cells/kg yield. We con-
sider the cost-benefit of G-CSF plus plerixafor (G + P) vs G-CSF
alone (G) for stem cell mobilization in NHL patients undergoing
ASCT.
Methods: We constructed a decision analytic model comparing
G + P to G in patients with NHL. The probabilities in the model
were taken from a recent randomized trial at Washington Univer-
sity (n5 41) comparing these two mobilization regimens. In the
trial, patients received G + P or G+placebo for initial mobilization.
In both arms, if minimal goal of 2  106 CD34 cells/kg was not
achieved after 4 aphereses, remobilization was conducted with
G + P. The model estimated costs for mobilization and remobiliza-
tion, but didn’t consider the transplant. The payor perspective was
taken with allowed charges, including medication, estimated using
Medicare allowable.
Results: In the G + P arm all patients (21/21) achieved the minimal
goal of CD34 cells after initial mobilization and proceeded to ASCT,
while in the G arm only 12/20 proceeded to ASCT. Of 8/20 remain-
ing G-patients, 2 were never remobilized, 6 were remobilized, but of
these only 4/6 achieved the minimal CD34 cell count required and
proceeded to ASCT. Adjusting for the lower enrollment in the G
arm, total allowed charges for mobilization of patients in the G + P
arm was $109,480 more than patients in the G arm. Had additional
mobilization been attempted for those patients in the G arm who
failed mobilization or remobilization (n5 4), the costs in the G
arm would have increased by $69,512, reducing the difference be-
tween groups to $39,968. We didn’t consider treatment or social
costs associated with the decision not to transplant following a failed
mobilization, as the events associated with these care processes were
not tracked in the trial. Conclusions: Taking a cost-benefit approach
we found that the G + P regimen in this trial cost $1,998 per patient
more than the G. This additional cost resulted in a 20% greater
probability of transplant in theG + P arm. Given the small difference
in cost, and large potential benefit, it is expected that future analyses
considering the social benefit of successful transplant will show that
the G + P regimen easily meets most accepted standards of cost-ef-
fectiveness.
G1 Placebo G1 PProbability of transplant 80.0% (16/20) 100% (21/21)
Probability of
remobilization
30.0% ( 6/20) N/ATotal cost per patient (SD) $ 12,458 (13,193) $ 17,932 (8,206)
Incremental cost per
patient
$ 5,474Estimated cost per
remobilization*$ 17,376Incremental cost after
adjustment for failed
mobilization$ 1,998*Remobilization protocol included plerixfor146
HEMATOPOIETIC STEM CELL APHERESIS PRODUCTS WITH HIGH MID-
COLLECTIONWBC COUNTS ARE AN ACCURATE INDICATOROF THE FINAL
PRODUCT WBC COUNT AND ARE ASSOCIATED WITH TRANSPLANT RE-
LATED ADVERSE EVENTS
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We randomly reviewed 159 patients (pts) at our institution who
underwent hematopoietic stem cell (HSC) collection with either
a COBE spectra cell separator (CS) (n5 85) or Fresenius AS 104
cell separator (F) (n5 74). Products collected using the CS had
higher total WBC count when compared to the F (163 +/- 136 K/
uL vs. 55 +/- 29 K/uL, p\0.001) but a lower percentage of mono-
nuclear cells (MNC) (75% +/- 23% vs. 85% +/- 11%, p\0.001).
Unexpected transplant related adverse events were seen in 3 pts
who experienced tonic-clonic seizures and 1 pt with delayed engraft-
ment. These pts all received HSC apheresis products with WBC
counts over 590 K/uL, which was significantly higher than the me-
dian WBC counts on all apheresis products, and all were collected
using CS. No apheresis products were diluted prior to cryopreserva-
tion or infusion.
We subsequently reviewed 21 consecutive HSC apheresis prod-
ucts from 13 separate pts and analyzed WBC, MNC, and CD34
cell counts at 3 different time points, pre, mid and post-collec-
tion. Apheresis products with WBC counts greater than 400 K/
uL were diluted with normal saline (NS) prior to cryopreserva-
tion. Pts’ diagnoses were comprised only of hematological malig-
nancies, and included both auto (n5 19) and allogeneic (n5 2)
HSC collections. Products were collected using the CS (n5 10)
and the F (n5 11). Two pts had post collection WBC counts
over 400 K/uL and both were collected using the CS. Both prod-
ucts were diluted with NS prior to cryopreservation. One of the
two products was associated with delayed engraftment and 84%
donor chimerism at day 100. No other transplant related adverse
events were identified.
Analysis of the pre, mid, and post cell counts on theHSC apheresis
products revealed mid WBC values that accurately predicted post
apheresis product WBC counts (Table). The ease and rapidity of
mid apheresis WBC count analysis may allow the apheresis proce-
dure to be modified if WBC counts greater than 400 K/ul are pre-
dicted. We plan to prospectively assess mid WBC counts on all
apheresis procedures that use CS. Products with mid
WBC. 400 K/uL will get additional plasma collected so the final
product can be diluted with autologous plasma. Accurate and timely
identification of high risk apheresis products can obviate the unnec-
essary dilution of all products and therefore help decrease the cost
associated with cryopreservation of apheresed HSC products.
WBC, MNC and CD 34 Cell Counts Mid and Post Apheresis
WBC (k/uL) MNC (%) CD34x106/kgCOBE MID POST MID POST MID POSTMEAN 1/- SD 273 1/- 230 281 1/- 186 76 1/- 22 86 1/- 16 3 1/- 4 6 1/- 8RANGE 819 596 75 53 9 23FRESENIUS MID POST MID POST MID POSTMEAN 1/- SD 71 1/- 22 75 1/- 20 88 1/- 5 90 1/- 5 1 1/- 0.8 2 1/- 1RANGE 69 67 20 16 2 4Mid - cell counts mid way through a 10-12 L collection, Post -cell counts
at the end of a 20-24 L collection147
RELATIVE EFFICIENCY OF CORD BLOOD RBC DEPLETION BY SEPAX ELU-
TRIATION AND MANUAL REDUCTION
Miller, C.N., Miller, S.N., Flannery, S., Stockinger, S., Gutman, J.,
Quinones, R., Freed, B.M. University of Colorado Denver ClinImmune
Labs, Aurora, CO
Infusion of cord blood units with high RBC volume has been re-
ported to increase the health risk for recipients. Therefore the
